Jaguar Health Drops 59%, Viking Therapeutics Falls 4%
On Wednesday morning trading on September 23, 2026, two biotechnology stocks—Jaguar Health and Viking Therapeutics—experienced significant declines. Jaguar Health (NASDAQ: JAGX) fell by nearly 59% to $14.21 with no verified catalyst identified; the drop is likely due to profit-taking following a strong prior run. The stock remains up about 9% for the month despite this decline. Viking Therapeutics (NASDAQ: VKTX), on the other hand, dropped by 4%, settling at $39.11 after previously rising sharply in response to positive top-line data from an obesity drug trial and a scheduled investor call. The current drop appears as a pullback following that news rather than a reversal of momentum. The broader biotechnology sector, represented by the iShares Biotechnology ETF (NASDAQ: IBB), remained nearly flat at -0.1%, while the SPDR S&P 500 ETF Trust (NYSEARCA: SPY) fell more significantly (-0.44%). This suggests that both declines are company-specific and not indicative of a broader sector selloff.
Tickers: $VKTX
Topics: biotechnology Jaguar Health stock decline Viking Therapeutics